Cannabis legalization in Canada is coming this summer. At press, the Cannabis Act, Bill C45, has been approved by the Senate. This legislation, aimed at restricting access for Canadian youth to cannabis while curbing the organized criminal activity associated with the distribution of this illegal substance, will allow Canadian adults to possess up to 30 grams of legal cannabis and grow up to four plants at home [1–3].

While there is some conclusive evidence supporting cannabis use for treatment of some illnesses—see Whiting et al. [4] and the Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda [5] for further details—the associated risks of use may be of particular interest to our readership.

While difficult to rule out residual confounding with concurrent tobacco use, lifetime combustible cannabis use was associated with a 2.12 hazard ratio of developing tracheal, bronchus, or lung cancer over non-users [6]. The acute intoxicating effects of use have been associated with a higher risk of motor vehicle collision [7–9] and marginally associated with fatal and serious injury [10]. Long-term use has been associated with a host of mental health, developmental, and psychosocial outcomes; curious readers are directed to the World Health Organization’s recent comprehensive review of the health effects of cannabis use [10].

To mitigate these risks, Fischer et al. [11] recently updated the Lower Risk Cannabis Use Guidelines in the Canadian context. Following a comprehensive review of the literature, 10 recommendations to reduce the harms associated with use are presented. Health care practitioners of all professions are encouraged to review and familiarize themselves with these guidelines so that they may engage in dialogue with users, or those considering cannabis use, in efforts to mitigate the public health impacts, especially in the context of legalization.

Statistics Canada’s 2017 Canadian Cannabis Survey reveals an overall past 12-month cannabis use prevalence of 21.7%; higher use among males than females was noted; 26.1% compared with 17.5%, respectively. Among age groups, those aged 20–24 years reported highest rates of use, with the age group 16–19 years reporting slightly lower use, and among the 25+ years age group 18.4% reported use [12]. In a survey of substance use among Canadian students in grades 6–12 in 2014–2015, 17% of respondents reported past year cannabis use [13]. In the 2004–2015 period, reported cannabis use trends decreased among 15–17-year-old females and all 18–24 year olds, remained stable among 15–17-year-old males, and showed an increasing trend among individuals of both sexes aged 25 years and older [14]. While steps are often taken to adjust for any bias in self-reported use, it is widely understood that self-reported use of illicit substances is under reported.

These figures, and a forthcoming time series study by our research group on the harms and costs of substance use in Canada, provide a baseline from which to measure the effect of legalization on the epidemiology of cannabis use, health outcomes, crime rates, and socioeconomic factors. Such with other legal psychoactive or habit-forming substances—namely alcohol and tobacco—it is the responsibility of the health care practitioner to remain informed of the most up to date and robust evidence of the benefits, risks, harms, and mitigating factors of cannabis use and to translate this knowledge to their patients in language and a medium that will be accepted and understood.

One benefit of legalization of cannabis in Canada is certain: this research is going to be a lot easier to carry out as more robust data are available for analysis!

REFERENCES

1. Tasker J. Trudeau vows cannabis will be legal by summer as senators urge delay. CBC News. 2018 May 3. Available at: http://www.cbc.ca/news/politics/cannabis-trudeau-legal-summer-1.4647026 (accessed May 9, 2018).

2. Legalization and Regulation of Cannabis – Canada.ca. Available at: https://www.canada.ca/en/services/policing/justice/legalization-regulation-marijuana.html (accessed May 9, 2018).

3. LEGISinfo – House Government Bill C-45 (42-1). Available at: http://www.parl.ca/LegisInfo/BillDetails.aspx?Bill=C45&Language=E&Mode=1&Parl=42&Ses=1 (accessed May 9, 2018).

4. Whiting PF, Wolff RF, Deshpande S, et al., Cannabinoids for medical use a systematic review and meta-analysis. JAMA 2015;313(24): 2456. doi: 10.1001/jama.2015.6358.

5. Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda, National Academies of Sciences, Engineering, and Medicine, Board on Population Health and Public Health Practice & Health and Medicine Division, editor. Therapeutic effects of cannabis and cannabinoids. In: The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: National Academies Press (US); 2017. Available at: https://www.ncbi.nlm.nih.gov/books/NBK425767/ (accessed May 9, 2018).

6. Callaghan RC, Allebeck P, Sidorchuk A, Marijuana use and risk of lung cancer: A 40-year cohort study Marijuana use and risk of lung cancer: A 40-year cohort study. Cancer Causes Control 2013;24(24). Available at: http://www.ncbi.nlm.nih.gov/books/NBK425767/ (accessed May 9, 2018).

7. Asbridge M, Hayden JA, Cartwright JL, Acute cannabis consumption and motor vehicle collision risk: Systematic review of observational.
studies and meta-analysis. BMJ 2012; 344(feb09 2): e536. doi: 10.1136/bmj.e536.

8. Li M-C, Brady JE, Dimaggio CJ, Lusardi AR, Tsong KY, Li G. Marijuana use and motor vehicle crashes. Epidemiol Rev 2012; 34(1): 65–72. doi: 10.1093/epirev/mxr017.

9. Elvik R., Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev 2013;60: 254–67. doi: 10.1016/j.aap.2012.06.017.

10. World Health Organisation. The health and social effects of nonmedical cannabis use. WHO; 2016. 95 p. Available at: http://www.who.int/substance_abuse/publications/cannabis_report/en/index5.html (accessed May 9, 2018).

11. Fischer B, Jeffries V, Hall W, Room R, Goldner E, Rehm J., Lower risk cannabis use guidelines for Canada (LRCUG): A narrative review of evidence and recommendations. Can J Public Health 2011;102: 324–7. doi: 10.17269/cjph.102.2738

12. The Canadian cannabis survey; Methodological report. Available at: http://epe.lac-bac.gc.ca/100/200/301/pwgsc-tsgsc/por-et/health/2017/102-16e/index.html (accessed May 9, 2018).

13. Summary of results: Canadian student tobacco, alcohol and drugs survey 2014–15 – Canada.ca. Health Canada 2016; Available at: https://www.canada.ca/en/health-canada/services/canadian-student-tobacco-alcohol-drugs-survey/2014-2015-summary.html (accessed May 9, 2018).

14. Rotermann M, Macdonald R. Analysis of trends in the prevalence of cannabis use in Canada, 1985 to 2015. Available at: http://www.statcan.gc.ca/pub/82-003-x/2018002/article/54908-eng.pdf (accessed May 9, 2018).